Analysis of melanoma cells in peripheral blood by reverse transcription- polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: A comparison with the whole blood guanidinium isothiocyanate RNA isolation method

Melanoma Research

Volumn 10, Issue 2, 2000, Pages 119-126

  De Vries, T J ^a   Fourkour, A ^a   Punt, C J A ^a,b   Ruiter, D J ^a   Van Muijen, G N P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Circulating tumour cells; MART 1 MelanA; RNA isolation method; RT PCR; Tyrosinase

Indexed keywords

GUANIDINE; ISOTHIOCYANIC ACID; MONOPHENOL MONOOXYGENASE; RNA;

ARTICLE; CELL ISOLATION; DIAGNOSTIC VALUE; ENZYME ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MELANOMA CELL; METASTASIS POTENTIAL; MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

EID: 0034102614     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200010020-00004     Document Type: Article

References (23)

1. 1. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227-1229.
2. 2. Keilholz U, Willhauck M, Scheibenbogen C, De Vries TJ, Burchill S. Polymerase chain reaction detection of circulating tumour cells. Melanoma Res 1997; 7: S133-S141.
3. 3. Keilholz U, Willhauck M, Rimoldi D, et al. Reliability of RT-PCR-based assays for detection of circulating tumour cells: a quality-assurance initiative of the EORTC melanoma cooperative group. Eur J Cancer 1998; 34: 750-753.
4. 4. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
5. 5. Brossart P, Schmier J-W, Kruger S, et al. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995; 55: 4065-4068.
6. 6. Brossart P, Keilholz U, Scheibenbogen C, Mohler T, Willhauck M, Hunstein W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunother 1994; 15: 38-41.
7. 7. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Mohler T, Hunstein W. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993; 101: 887-889.
8. 8. Farthmann B, Eberle J, Krasagatis K, et al. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol 1998; 110: 263-268.
9. 9. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998; 16: 1760-1769.
10. 10. De Vries TJ, Fourkour A, Punt CJA, et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative PCR. Br J Cancer 1999; 80: 883-891.
11. 11. Foss AJE, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995; 72: 155-159.
12. 12. Tobal K, Sherman LS, Foss AJE, Lightman SL. Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. Invest Ophthalmol Vis Sci 1993; 34: 2622-2625.
13. 13. Kunter U, Buer J, Probst M, et al. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996; 88: 590-594.
14. 14. Hoon DS, Wang Y, Dale PS, et al. Detection of occult melanoma cells in the blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13: 2109-2116.
15. 15. Mellado B, Colomer D, Castel T, et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 1996; 14: 2091-2097.
16. 16. Reinhold U, Ludtke-Handjery H-C, Schnautz S, Kreysel H-W, Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997; 108: 166-169.
17. 17. Ghossein RA, Coit D, Brennan M, et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res 1998; 4: 419-428.
18. 18. Battayani Z, Grob JJ, Xerri L, et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995; 131: 443-447.
19. 19. Jung FA, Buzaid AC, Ross MI, et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997; 15: 2826-2831.
20. 20. De Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, Van Muijen GNP. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1 and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997; 57: 3223-3229.
21. 21. De Vries TJ, Trancikova D, Ruiter DJ, Van Muijen GNP. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer 1998; 78: 1156-1161.
22. 22. De Vries TJ, Fourkour A, Punt CJA, Diepstra H, Ruiter DJ, Van Muijen GNP. Melanoma inhibiting activity (MIA) is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood. Br J Cancer 1999; 81: 1066-1070.
23. 23. Ferrier CM, Van Geloof WL, De Witte HH, Kramer MD, Ruiter DJ, Van Muijen GNP. Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. J Histochem Cytochem 1999; 46: 469-476.